Development and Validation of a Scalable Next-Generation Sequencing System for Assessing Relevant Somatic Variants in Solid Tumors

Neoplasia (United States)

Volumn 17, Issue 4, 2015, Pages 385-399

  Hovelson, Daniel H ^a   McDaniel, Andrew S ^a   Cani, Andi K ^a   Johnson, Bryan ^b   Rhodes, Kate ^b   Williams, Paul D ^b   Bandla, Santhoshi ^b   Bien, Geoffrey ^b   Choppa, Paul ^b   Hyland, Fiona ^b   Gottimukkala, Rajesh ^b   Liu, Guoying ^b   Manivannan, Manimozhi ^b   Schageman, Jeoffrey ^b   Ballesteros Villagrana, Efren ^b   Grasso, Catherine S ^c   Quist, Michael J ^c   Yadati, Venkata ^a   Amin, Anmol ^a   Siddiqui, Javed ^a   Betz, Bryan L ^a   Knudsen, Karen E ^d   Cooney, Kathleen A ^a   Feng, Felix Y ^a   Roh, Michael H ^a   Nelson, Peter S ^e   Liu, Chia Jen ^a   Beer, David G ^a   Wyngaard, Peter ^b   Chinnaiyan, Arul M ^a   Sadis, Seth ^b   Rhodes, Daniel R ^a,b   Tomlins, Scott A ^a   more..

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b Thermo Fisher Scientific   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d THOMAS JEFFERSON UNIVERSITY   (United States)

^e Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; B RAF KINASE; BETA CATENIN; DNA; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; FORMALDEHYDE; K RAS PROTEIN; PARAFFIN; RNA; TRANSCRIPTION FACTOR ERG; CTNNB1 PROTEIN, HUMAN; ERG PROTEIN, HUMAN; KRAS PROTEIN, HUMAN; ONCOPROTEIN; PROTEIN P21; PROTEIN TYROSINE KINASE; RAS PROTEIN; SERINE PROTEINASE; TMPRSS2 PROTEIN, HUMAN; TRANSACTIVATOR PROTEIN;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BIOINFORMATICS; BLADDER TUMOR; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER TISSUE; CONTROLLED STUDY; COPY NUMBER VARIATION; DNA RNA HYBRIDIZATION; FEMALE; GAIN OF FUNCTION MUTATION; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; GENE FUSION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOME; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INDEL MUTATION; KNOWLEDGE BASE; LOSS OF FUNCTION MUTATION; MAJOR CLINICAL STUDY; MALE; MOLECULAR GENETICS; MULTIPLEX POLYMERASE CHAIN REACTION; MUTATIONAL ANALYSIS; NEXT GENERATION SEQUENCING; NONSENSE MUTATION; PERSONALIZED MEDICINE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE CANCER; RETROSPECTIVE STUDY; SOLID TUMOR; SOMATIC MUTATION; TMPRSS2 GENE; TRANSLATIONAL RESEARCH; TUMOR GENE; VALIDATION STUDY; BIOLOGY; DNA MUTATIONAL ANALYSIS; GENETICS; HIGH THROUGHPUT SEQUENCING; MIDDLE AGED; MUTATION; NEOPLASM; PROCEDURES;

AGED; BETA CATENIN; COMPUTATIONAL BIOLOGY; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; FEMALE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MALE; MIDDLE AGED; MUTATION; NEOPLASMS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS P21(RAS); RAS PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; SERINE ENDOPEPTIDASES; TRANS-ACTIVATORS; TRANSCRIPTIONAL REGULATOR ERG;

EID: 84983535287     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1016/j.neo.2015.03.004     Document Type: Article

References (56)

1. [1] Garraway, LA, Verweij, J, Ballman, KV, Precision oncology: an overview. J Clin Oncol 31 (2013), 1803–1805.
2. [2] Mendelsohn, J, Personalizing oncology: perspectives and prospects. J Clin Oncol 31 (2013), 1904–1911.
3. [3] Arteaga, CL, Baselga, J, Impact of genomics on personalized cancer medicine. Clin Cancer Res 18 (2012), 612–618.
4. [4] McDermott, U, Downing, JR, Stratton, MR, Genomics and the continuum of cancer care. N Engl J Med 364 (2011), 340–350.
5. [5] Pant, S, Weiner, R, Marton, MJ, Navigating the rapids: the development of regulated next-generation sequencing-based clinical trial assays and companion diagnostics. Front Oncol, 4, 2014, 78.
6. [6] Olsen, D, Jorgensen, JT, Companion diagnostics for targeted cancer drugs—clinical and regulatory aspects. Front Oncol, 4, 2014, 105.
7. [7] Parkinson, DR, Johnson, BE, Sledge, GW, Making personalized cancer medicine a reality: challenges and opportunities in the development of biomarkers and companion diagnostics. Clin Cancer Res 18 (2012), 619–624.
8. [8] Mass, RD, Press, MF, Anderson, S, Cobleigh, MA, Vogel, CL, Dybdal, N, Leiberman, G, Slamon, DJ, Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab. Clin Breast Cancer 6 (2005), 240–246.
9. [9] Druker, BJ, Translation of the Philadelphia chromosome into therapy for CML. Blood 112 (2008), 4808–4817.
10. [10] Kris, MG, Johnson, BE, Berry, LD, Kwiatkowski, DJ, Iafrate, AJ, Wistuba, II, Varella-Garcia, M, Franklin, WA, Aronson, SL, Su, PF, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA 311 (2014), 1998–2006.
11. [11] Lawrence, MS, Stojanov, P, Mermel, CH, Robinson, JT, Garraway, LA, Golub, TR, Meyerson, M, Gabriel, SB, Lander, ES, Getz, G, Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 505 (2014), 495–501.
12. [12] Lawrence, MS, Stojanov, P, Polak, P, Kryukov, GV, Cibulskis, K, Sivachenko, A, Carter, SL, Stewart, C, Mermel, CH, Roberts, SA, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499 (2013), 214–218.
13. [13] Vogelstein, B, Papadopoulos, N, Velculescu, VE, Zhou, S, Diaz, LA Jr., Kinzler, KW, Cancer genome landscapes. Science 339 (2013), 1546–1558.
14. [14] Zack, TI, Schumacher, SE, Carter, SL, Cherniack, AD, Saksena, G, Tabak, B, Lawrence, MS, Zhang, CZ, Wala, J, Mermel, CH, et al. Pan-cancer patterns of somatic copy number alteration. Nat Genet 45 (2013), 1134–1140.
15. [15] Tomlins, SA, Wyngaard, P, Khazanov, N, Williams, P, Bowden, E, Sadis, S, Rhodes, DR, Analysis of 2,700 cancer exomes to identify novel cancer drivers and therapeutic opportunities. Eur J Cancer, 48, 2012, 134.
16. [16] Beadling, C, Neff, TL, Heinrich, MC, Rhodes, K, Thornton, M, Leamon, J, Andersen, M, Corless, CL, Combining highly multiplexed PCR with semiconductor-based sequencing for rapid cancer genotyping. J Mol Diagn 15 (2013), 171–176.
17. [17] Borad, MJ, Champion, MD, Egan, JB, Liang, WS, Fonseca, R, Bryce, AH, McCullough, AE, Barrett, MT, Hunt, K, Patel, MD, et al. Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma. PLoS Genet, 10, 2014, e1004135.
18. [18] Frampton, GM, Fichtenholtz, A, Otto, GA, Wang, K, Downing, SR, He, J, Schnall-Levin, M, White, J, Sanford, EM, An, P, et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol 31 (2013), 1023–1031.
19. [19] Grasso, C, Butler, T, Rhodes, K, Quist, M, Neff, TL, Moore, S, Tomlins, SA, Reinig, E, Beadling, C, Andersen, M, et al. Assessing copy number alterations in targeted, amplicon-based next-generation sequencing data. J Mol Diagn 17 (2015), 53–63.
20. [20] Hadd, AG, Houghton, J, Choudhary, A, Sah, S, Chen, L, Marko, AC, Sanford, T, Buddavarapu, K, Krosting, J, Garmire, L, et al. Targeted, high-depth, next-generation sequencing of cancer genes in formalin-fixed, paraffin-embedded and fine-needle aspiration tumor specimens. J Mol Diagn 15 (2013), 234–247.
21. [21] Roychowdhury, S, Iyer, MK, Robinson, DR, Lonigro, RJ, Wu, YM, Cao, X, Kalyana-Sundaram, S, Sam, L, Balbin, OA, Quist, MJ, et al. Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci Transl Med, 3, 2011, 111ra121.
22. [22] Singh, RR, Patel, KP, Routbort, MJ, Reddy, NG, Barkoh, BA, Handal, B, Kanagal-Shamanna, R, Greaves, WO, Medeiros, LJ, Aldape, KD, et al. Clinical validation of a next-generation sequencing screen for mutational hotspots in 46 cancer-related genes. J Mol Diagn 15 (2013), 607–622.
23. [23] Van Allen, EM, Wagle, N, Stojanov, P, Perrin, DL, Cibulskis, K, Marlow, S, Jane-Valbuena, J, Friedrich, DC, Kryukov, G, Carter, SL, et al. Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine. Nat Med, 20, 2014.
24. [24] Zheng, Z, Liebers, M, Zhelyazkova, B, Cao, Y, Panditi, D, Lynch, KD, Chen, J, Robinson, HE, Shim, HS, Chmielecki, J, et al. Anchored multiplex PCR for targeted next-generation sequencing. Nat Med 20 (2014), 1479–1484.
25. [25] Hoogstraat, M, Hinrichs, JW, Besselink, NJ, Radersma-van Loon, JH, de Voijs, CM, Peeters, T, Nijman, IJ, de Weger, RA, Voest, EE, Willems, SM, et al. Simultaneous detection of clinically relevant mutations and amplifications for routine cancer pathology. J Mol Diagn 17 (2015), 10–18.
26. [26] Samorodnitsky, E, Datta, J, Jewell, BM, Hagopian, R, Miya, J, Wing, MR, Damodaran, S, Lippus, JM, Reeser, JW, Bhatt, D, et al. Comparison of custom capture for targeted next-generation DNA sequencing. J Mol Diagn 17 (2015), 64–75.
27. [27] Forbes, SA, Beare, D, Gunasekaran, P, Leung, K, Bindal, N, Boutselakis, H, Ding, M, Bamford, S, Cole, C, Ward, S, et al. COSMIC: exploring the world's knowledge of somatic mutations in human cancer. Nucleic Acids Res 43 (2015), D805–D811.
28. [28] Rhodes, DR, Kalyana-Sundaram, S, Mahavisno, V, Varambally, R, Yu, J, Briggs, BB, Barrette, TR, Anstet, MJ, Kincead-Beal, C, Kulkarni, P, et al. Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia 9 (2007), 166–180.
29. [29] Grasso, CS, Wu, YM, Robinson, DR, Cao, X, Dhanasekaran, SM, Khan, AP, Quist, MJ, Jing, X, Lonigro, RJ, Brenner, JC, et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 487 (2012), 239–243.
30. [30] Grasso, CS, Cani, AK, Hovelson, DH, Quist, MJ, Douville, NJ, Yadati, V, Amin, AM, Nelson, PS, Betz, BL, Liu, CJ, et al. Integrative molecular profiling of routine clinical prostate cancer specimens. Ann Oncol, 2015 [Epub ahead of print].
31. [31] Warrick, JI, Hovelson, DH, Amin, A, Liu, C-J, Cani, AK, McDaniel, AS, Yadati, V, Quist, MJ, Weizer, AZ, Brenner, CJ, et al. Tumor evolution and progression in multifocal and paired non-invasive/invasive urothelial carcinoma. Virchows Arch 466 (2015), 297–311.
32. [32] Cani, AK, Hovelson, DH, McDaniel, AS, Sadis, S, Haller, MJ, Yadati, V, Amin, AM, Bratley, J, Bandla, S, Williams, PD, et al. Next-Gen sequencing exposes frequent MED12 mutations and actionable therapeutic targets in phyllodes tumors. Mol Cancer Res, 2015 [Epub ahead of print].
33. [33] McDaniel, AS, Zhai, Y, Cho, KR, Dhanasekaran, SM, Montgomery, JS, Palapattu, G, Siddiqui, J, Morgan, T, Alva, A, Weizer, A, et al. HRAS mutations are frequent in inverted urothelial neoplasms. Hum Pathol 45 (2014), 1957–1965.
34. [34] Palanisamy, N, Ateeq, B, Kalyana-Sundaram, S, Pflueger, D, Ramnarayanan, K, Shankar, S, Han, B, Cao, Q, Cao, X, Suleman, K, et al. Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nat Med 16 (2010), 793–798.
35. [35] Weir, BA, Woo, MS, Getz, G, Perner, S, Ding, L, Beroukhim, R, Lin, WM, Province, MA, Kraja, A, Johnson, LA, et al. Characterizing the cancer genome in lung adenocarcinoma. Nature 450 (2007), 893–898.
36. [36] Tomlins, SA, Molecular clues assist in the cancer clinic. Sci Transl Med, 5, 2013, 193fs126.
37. [37] Tomlins, SA, Rhodes, DR, Perner, S, Dhanasekaran, SM, Mehra, R, Sun, XW, Varambally, S, Cao, X, Tchinda, J, Kuefer, R, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310 (2005), 644–648.
38. [38] Wang, J, Cai, Y, Ren, C, Ittmann, M, Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer. Cancer Res 66 (2006), 8347–8351.
39. [39] Robert, C, Karaszewska, B, Schachter, J, Rutkowski, P, Mackiewicz, A, Stroiakovski, D, Lichinitser, M, Dummer, R, Grange, F, Mortier, L, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med 372 (2015), 30–39.
40. [40] Long, GV, Stroyakovskiy, D, Gogas, H, Levchenko, E, de Braud, F, Larkin, J, Garbe, C, Jouary, T, Hauschild, A, Grob, JJ, et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med 371 (2014), 1877–1888.
41. [41] Baca, SC, Prandi, D, Lawrence, MS, Mosquera, JM, Romanel, A, Drier, Y, Park, K, Kitabayashi, N, MacDonald, TY, Ghandi, M, et al. Punctuated evolution of prostate cancer genomes. Cell 153 (2013), 666–677.
42. [42] Nakata, T, Kitamura, Y, Shimizu, K, Tanaka, S, Fujimori, M, Yokoyama, S, Ito, K, Emi, M, Fusion of a novel gene, ELKS, to RET due to translocation t(10;12)(q11;p13) in a papillary thyroid carcinoma. Genes Chromosomes Cancer 25 (1999), 97–103.
43. [43] Lu, C, Luo, J, Decoding the androgen receptor splice variants. Transl Androl Urol 2 (2013), 178–186.
44. [44] Antonarakis, ES, Lu, C, Wang, H, Luber, B, Nakazawa, M, Roeser, JC, Chen, Y, Mohammad, TA, Fedor, HL, Lotan, TL, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med 371 (2014), 1028–1038.
45. [45] Kong-Beltran, M, Seshagiri, S, Zha, J, Zhu, W, Bhawe, K, Mendoza, N, Holcomb, T, Pujara, K, Stinson, J, Fu, L, et al. Somatic mutations lead to an oncogenic deletion of met in lung cancer. Cancer Res 66 (2006), 283–289.
46. [46] Druillennec, S, Dorard, C, Eychene, A, Alternative splicing in oncogenic kinases: from physiological functions to cancer. J Nucleic Acids, 2012, 2012, 639062.
47. [47] Barbieri, CE, Tomlins, SA, The prostate cancer genome: perspectives and potential. Urol Oncol 32:53 (2014), e15–e22.
48. [48] Beltran, H, Rubin, MA, New strategies in prostate cancer: translating genomics into the clinic. Clin Cancer Res 19 (2013), 517–523.
49. [49] Brenner, JC, Chinnaiyan, AM, Tomlins, SA, ETS fusion genes in prostate cancer. Tindall, DJ, (eds.) Vol. Protein Reviews, 2013, Springer New York, New York, 139–183.
50. [50] Rubin, MA, Maher, CA, Chinnaiyan, AM, Common gene rearrangements in prostate cancer. J Clin Oncol 29 (2011), 3659–3668.
51. [51] Beltran, H, Tomlins, S, Aparicio, A, Arora, V, Rickman, D, Ayala, G, Huang, J, True, L, Gleave, ME, Soule, H, et al. Aggressive variants of castration-resistant prostate cancer. Clin Cancer Res 20 (2014), 2846–2850.
52. [52] Chen, H, Sun, Y, Wu, C, Magyar, CE, Li, X, Cheng, L, Yao, JL, Shen, S, Osunkoya, AO, Liang, C, et al. Pathogenesis of prostatic small cell carcinoma involves the inactivation of the P53 pathway. Endocr Relat Cancer 19 (2012), 321–331.
53. [53] Bluemn, EG, Nelson, PS, The androgen/androgen receptor axis in prostate cancer. Curr Opin Oncol 24 (2012), 251–257.
54. [54] Kumar, A, White, TA, MacKenzie, AP, Clegg, N, Lee, C, Dumpit, RF, Coleman, I, Ng, SB, Salipante, SJ, Rieder, MJ, et al. Exome sequencing identifies a spectrum of mutation frequencies in advanced and lethal prostate cancers. Proc Natl Acad Sci U S A 108 (2011), 17087–17092.
55. [55] Rajan, P, Sudbery, IM, Villasevil, ME, Mui, E, Fleming, J, Davis, M, Ahmad, I, Edwards, J, Sansom, OJ, Sims, D, et al. Next-generation sequencing of advanced prostate cancer treated with androgen-deprivation therapy. Eur Urol 66 (2014), 32–39.
56. [56] Beltran, H, Yelensky, R, Frampton, GM, Park, K, Downing, SR, Macdonald, TY, Jarosz, M, Lipson, D, Tagawa, ST, Nanus, DM, et al. Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity. Eur Urol 63 (2013), 920–926.